Authors

Coaching Flag Football—And Guiding a Biotech Through Commercialization

Useful tips and parallels for staying in the game following a complete response letter.

Agentic AI and the Future of Commercial Excellence in Life Sciences

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Optimizing next-generation sequencing for precision oncology trials

This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Executive Presence: The Leadership Edge Pharma Leaders Can't Afford to Overlook

Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership impact.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

From Lab to Market: Tracking Today’s Shifting Pathways for Biotech

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Fair Market Value vs. Current Market Leverage

How pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution services

Rethinking Market Access in CEE: Time to Bust the Myths

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Challenging Cases®: Firsthand insight into oncology decision‑making

Through interactive, quantitative live and virtual double-blinded case-based sessions followed by a national key opinion leader data-focused discussion, Challenging Cases offers a window into how oncologists select treatment options, balance clinical considerations, and respond to complex patient scenarios, providing insight into the factors shaping real-world treatment decisions.

Hospital Pharmacy and Supply Chain Leaders Want to Be Heard: Are you Ready to Listen?

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

The Direct-to-Patient Balance Sheet: Increased Access, Decreased Friction and Trust Earned

DTP programs are redefining the manufacturer’s access operating model.

What is Daiichi Sankyo’s Post JP Morgan Strategy?

In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.

From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle

Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Agentic AI and the Future of Commercial Excellence in Life Sciences

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care

As therapeutic complexity increases, life sciences companies should cultivate open mindsets toward innovative data sources beyond traditional claims and electronic medical record data.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

From Uncertainty to Opportunity: Navigating IPAY 2028

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Three Imperatives Pharma Leaders Should Prioritize This Year

The business and market models drugmakers must continually adapt to stay competitive as 2026 progresses.

Your Trusted Resource for Mission Critical Solutions

There’s a reason your facility’s most sensitive operations are called “mission critical.” Learn how ABM’s highly technical management services can take the worry out of maintaining your most specialized systems.

Introducing Agentic AI: Its Revolutionary Potential in Pharma

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

AI Can’t Lead. Healthcare Needs Leaders

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

Advancing Circular Economy Packaging in Pharmaceutical Cold Chain

Site Satisfaction Is the New Competitive Advantage

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.